Fulgent expects full-year 2026 revenue of $330 million to $340 million.
Third-quarter cash reserves reached $652.4 million after a federal tax refund.
Laboratory AI slide image analysis volume grew 23% sequentially.
On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Fulgent (NASDAQ:FLGT) announced full-year 2026 revenue guidance of $330 million to $340 million. Cash reserves reached $652.4 million after the receipt of a federal tax refund, providing financial flexibility as laboratory collections recover. Three things management said stand out.
Management transitioned its revenue cycle management (RCM), billing, and collection software to increase operational efficiency across newly acquired laboratories. Customization delays temporarily depressed collection rates in prior quarters, but operational adjustments delivered immediate sequential margin gains.
While this transition continued to have a negative impact on the third quarter, we are pleased to announce we have made significant progress and have seen a positive sequential trend in reimbursement which has contributed to improvements in our total revenue and gross margins as compared to the second quarter.
-- Brandon Perthuis, Chief Commercial Officer
Laboratory automation relies on artificial intelligence (AI, software designed to automate visual pattern recognition) to process tissue samples with high precision. Fulgent has scaled processing volume while reducing software analysis errors, thereby driving diagnostic speed and creating operational efficiency as test volumes grow.
During the third quarter, our AI platform analyzed approximately 255 thousand slide images representing a 23% increase from the second quarter. Importantly, as utilization has scaled, the technical reliability of the platform has improved substantially. With failed analysis declining to just 0.01% during the quarter.
-- Brandon Perthuis, Chief Commercial Officer
Beyond diagnostic testing, Fulgent develops nanoencapsulated therapies designed to deliver cancer treatments directly to tumor cells while reducing side effects. Clinical development advanced for candidate FID-007 following a meeting with the Food and Drug Administration (FDA), moving the treatment closer to pivotal Phase 3 trials.
FID-007 is a nano-encapsulated peptide EXO developed under Fulgent's clean chemo platform. The platform is designed to reduce toxicity typically associated with conventional chemotherapy while maintaining or improving efficacy. A profile Fulgent delivery is preferable in combination oncology regimen.
-- Ming Hsieh, Chief Executive Officer
Operational momentum is building as billing software fixes take hold and clinical trials advance. Management prioritizes research and development (R&D) investments alongside sales integration, while monitoring reimbursement stability under the Protecting Access to Medicare Act (PAMA), a federal fee schedule framework.
We continue to prioritize our investment across 2 key areas: R&D, where we are advancing both our laboratory testing capabilities and clinical study pipeline and the integration of Bako Diagnostics and StrataDx where we are aligning our expanded sales organization, ... to drive productivity and operating efficiency.
-- Paul Kim, Chief Financial Officer
A cash balance of $652.4 million supports ongoing clinical drug development.
We believe we are well positioned for longer term growth and strategic investments, innovation and expanded offerings that deliver value.
-- Ming Hsieh, Chief Executive Officer
Before you buy stock in Fulgent Genetics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Fulgent Genetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
The Motley Fool has positions in and recommends Fulgent Genetics. The Motley Fool has a disclosure policy.